Literature DB >> 7678716

Changes in expression of differentiation markers between normal ovarian cells and derived tumors.

C C Van Niekerk1, F C Ramaekers, A G Hanselaar, J Aldeweireldt, L G Poels.   

Abstract

The marker profile of 18 samples of normal human ovarian tissues and 138 samples of their derived tumors was established using 51 monoclonal antibodies directed against intermediate filaments, ovarian carcinoma-specific antigens, general tumor-associated antigens and MHC-I/II antigens. Our data show that vimentin and keratins 7, 8, 18, and 19 were found in both epithelial and some nonepithelial ovarian tumors. Several tumor samples contained additional keratins 4, 10, 13, and 14, as well as desmin. BW 495/36 and to a lesser extent HMFG-2 were usually found in all ovarian tumors that contained simple epithelial keratins, except the absence of HMFG-2 in gonadal tumors as well as in dysgerminomas. In contrast to the keratin antibodies, these two panepithelial antibodies were negative in normal mesothelial cells and granulosa cells of the ovarian follicles. In general, the marker TAG-72 appeared useful for its discrimination between positively stained mucinous adenomas, the ovarian carcinomas as well as germ cell tumors, and the negatively stained gonadal tumors, serous adenomas, and cystomas. OV632 appeared useful in the distinction between negatively stained serous adenomas and positively stained serous carcinomas. In contrast, the monoclonal antibodies OC 125, OV-TL 3, OV-TL 16, and MOv 18 can be considered as pan-ovarian carcinoma markers, however without the discriminative capability as seen for OV632. These ovarian carcinoma-associated antigens were hardly found expressed in gonadal and germ cell tumors, except in the group of endodermal sinus tumors. HLA-I was found to be expressed in almost all nucleated cells, although loss of HLA-I expression was seen in areas of tumor cells. HLA-DR was negative in normal ovarian tissue, but heterogeneous expression was noticed in most of the epithelial tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678716      PMCID: PMC1886830     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Authors:  V G Johnson; J Schlom; A J Paterson; J Bennett; J L Magnani; D Colcher
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

Review 2.  Intermediate filament proteins in the study of tumor heterogeneity: an in-depth study of tumors of the urinary and respiratory tracts.

Authors:  F C Ramaekers; O Moesker; A Huysmans; G Schaart; G Westerhof; S S Wagenaar; C J Herman; G P Vooijs
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary.

Authors:  B Czernobilsky; R Moll; R Levy; W W Franke
Journal:  Eur J Cell Biol       Date:  1985-05       Impact factor: 4.492

4.  Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas.

Authors:  R Moll; S Pitz; R Levy; W Weikel; W W Franke; B Czernobilsky
Journal:  Hum Pathol       Date:  1991-10       Impact factor: 3.466

5.  Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos. 4 and 13.

Authors:  G N van Muijen; D J Ruiter; W W Franke; T Achtstätter; W H Haasnoot; M Ponec; S O Warnaar
Journal:  Exp Cell Res       Date:  1986-01       Impact factor: 3.905

6.  Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA).

Authors:  K Bosslet; G Lüben; A Schwarz; E Hundt; H P Harthus; F R Seiler; C Muhrer; G Klöppel; K Kayser; H H Sedlacek
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

7.  The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).

Authors:  C A Szpak; W W Johnston; V Roggli; J Kolbeck; S C Lottich; R Vollmer; A Thor; J Schlom
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

8.  Monoclonal antibody to keratin filaments, specific for glandular epithelia and their tumors. Use in surgical pathology.

Authors:  F Ramaekers; A Huysmans; O Moesker; A Kant; P Jap; C Herman; P Vooijs
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

9.  DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.

Authors:  F Vánky; E Klein; J Willems
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Cytokeratin and neurofilament in lung carcinomas.

Authors:  G N van Muijen; D J Ruiter; C van Leeuwen; F A Prins; K Rietsema; S O Warnaar
Journal:  Am J Pathol       Date:  1984-09       Impact factor: 4.307

View more
  13 in total

1.  Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties.

Authors:  M Kämäräinen; I Leivo; R Koistinen; M Julkunen; U Karvonen; E M Rutanen; M Seppälä
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

2.  Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.

Authors:  David R Soto-Pantoja; Jeff S Isenberg; David D Roberts
Journal:  J Genet Syndr Gene Ther       Date:  2011-09-26

Review 3.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

4.  Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma.

Authors:  Gozde Kir; Ayse Gurbuz; Ates Karateke; Mustafa Kir
Journal:  World J Gastrointest Surg       Date:  2010-04-27

5.  Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.

Authors:  J H Lagendijk; H Mullink; P J van Diest; G A Meijer; C J Meijer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

6.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers.

Authors:  Kathleen Hibbs; Keith M Skubitz; Stefan E Pambuccian; Rachael C Casey; Kathryn M Burleson; Theodore R Oegema; Jeannine J Thiele; Suzanne M Grindle; Robin L Bliss; Amy P N Skubitz
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 7.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

8.  Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.

Authors:  Thuy-Vy Do; Lena A Kubba; Hongyan Du; Charles D Sturgis; Teresa K Woodruff
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

9.  Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences.

Authors:  R Slobbe; L Poels; G ten Dam; O Boerman; L Nieland; J Leunissen; F Ramaekers; G van Eys
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

10.  Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.

Authors:  T Yanagibashi; I Gorai; T Nakazawa; E Miyagi; F Hirahara; H Kitamura; H Minaguchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.